The trial enrolled 703 participants who had previously received one or more lines of systemic therapy.

The setback dims the outlook for a medicine Pfizer sees as an important contributor going forward, though some analysts are ...

The drug, acquired in Pfizer's $43 billion purchase of Seagen, did not outlast standard chemotherapy in a 703-patient study ...

Things are going from bad to worse for the pharmaceutical giant.

PFE's phase III NSCLC study misses a key survival goal overall, but a large subgroup shows favorable survival trends vs ...

Pfizer's lung cancer drug trial update, oncology pipeline strategy, Seagen deal impact, and subgroup opportunity in non small ...

A post-marketing trial finds the oral antiviral achieves effective blood concentrations in at-risk children aged 6 years or older with mild-to-moderate COVID.

Pfizer (NYSE:PFE) oncology updates and IBRANCE expansion unfold within S&P 500 healthcare segment, alongside lung cancer ...

Pfizer’s high-stakes bet on antibody-drug conjugates (ADCs) has hit a speed bump. | Pfizer announced Monday that sigvotatug ...

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and ...

Pfizer (PFE) stock is in focus as the antibody-drug conjugate sigvotatug vedotin fails in a Phase 3 trial versus chemotherapy ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a ...